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arterial hypertension (PAH).
METHODS 818 case report forms from patients receiving tadalaﬁl
were collected from December 2009 (the drug launch time) to October
2013. The observation period was up to 2 years. 815 eligible patients
data was analyzed for safety and 765 PAH patients data was analyzed
for effectiveness. WHO functional classiﬁcation of PAH and 6-minute
walking test were used to evaluate effectiveness. The study was
conducted in accordance with the Good Post-marketing Study Practice
(GPSP) Ministerial Ordinance.
RESULTS The major patient characteristics were: median age (45.4
years), female (67.7%), and patient receiving tadalaﬁl for PAH treat-
ment (93.9%). 37.7% patients were with idiopathic PAH (IPAH), 2.0%
were familial PAH (FPAH), and 53.5% were associated with other
diseases (APAH) such as collagen vascular diseases (28.0%) and
congenital systemic-to-pulmonary shunts (23.9%). 31.17% of the pa-
tients developed drug-related treatment-emergent adverse events
(TEAEs) such as headache (8.83%), epistaxis (2.33%) and diarrhea
(2.21%), which is consistent with the existing safety proﬁle. As for
effectiveness, patients who improved more than 1 class of WHO
functional classiﬁcation (e.g. from Class II to Class I) were: 16.1% (120/
744) after 3 months treatment, 25.6% (73/285) after 12 months, and
32.4% (34/105) after 24 months. While patients who worsened over 1
class (e.g. from Class I to II) were: 1.5% (11/744) after 3 months, 1.4%
(4/285) after 12 month, and 4.8% (5/105) after 24 months. At the end of
observation (24 months since the administration), 6-minute walking
distance (6MWD) of 52 cases was increased by 51.7 m (mean distance
change, 95% CI, 23.0 – 80.4 m).
CONCLUSIONS The interim analysis of the All-Patient Investigation
suggests that no new safety concerns were identiﬁed in patients
receiving long-term tadalaﬁl treatment in daily clinical practice. Based
on the results of effectiveness analysis, in spite of limited numbers of
cases evaluated, improvement in effectiveness was noted in the
course of tadalaﬁl treatment.GW26-e5447
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OBJECTIVES In the current era of interventions, monitoring the
effectiveness of antiplatelet medications is vital. Considering the
emergence of antiplatelet resistance, reduced response to antiplatelet
therapy may leads to the stent thrombosis which is associated with
high morbidity and mortality. In the present study we evaluated the
effectiveness of thienopyridine-based antiplatelet regimens in post-
PCI patients using AggreGuide A-100 platelet aggregometer (Aggre-
dyne Inc., USA), a new, FDA-approved, easy-to-use, point-of-care
device developed to monitor platelet aggregation in whole blood us-
ing laser-light scattering technique.
METHODS In this prospective, single-center study, patients whore-
ceived antiplatelet therapy after undergoing coronary stent implan-
tation at an Indian tertiary care center during May-October, 2014 were
enrolled. Platelet aggregation was evaluated from the blood sample of
each study participant after 2–3 days of antiplatelet therapy using the
AggreGuideA-100. Test results were obtained as platelet activity index
(PAI), on a scale ranging from 0 to 10. Since the PAI value <2 is ob-
tained as no detectable aggregation during the test, such observations
were assigned the PAI value of 2. Test ﬁndings were interpreted as (a)
therapy working ifthe PAI value is 2–5 and (b) therapy not working if
the PAI value is above 5.
RESULTS A total of 220 patients (mean age: 55.359.51 years; 74.5%
males) were enrolled in the study. Among the study group, 79 (35.9%),
100 (45.5%), and 41 (18.6%) patients received Clopidogrel-, Prasugrel-,
and Ticagrelor based antiplatelet therapy respectively, at the discre-
tion of the treating physician. The AggreGuide A-100 testing indicated
that the effectiveness of antiplatelet therapy was inadequate in 43
(19.5%) patients. In particular, 30 (38.0%) patients receiving Clopi-
dogrel-, 11 (11.0%) patients receiving Prasugrel-, and 2 (4.9%) patients
receiving Ticagrelor- based antiplatelet therapy displayed inadequate
platelet response. Antiplatelet therapy was optimized accordingly for
these patients.
CONCLUSIONS Monitoring individual’s platelet activity should
become a new standard-of-care for patients on antiplatelet therapy.Using AggreGuide A-100, nearly 20% of patients were identiﬁed to
have inadequate response to thienopyridine-based antiplatelet ther-
apy in our study. Antiplatelet therapy was optimized accordingly for
these patients with inadequate response.
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OBJECTIVES Ticagrelor provides more consistent, rapid, and potent
platelet inhibition than clopidogrel, however, the interindividual
variability in response to ticagrelor was not absent. This study sought
to display the various distribution of ticagrelor antiplatelet respon-
siveness in Chinese acute coronary syndrome (ACS) patients.
METHODS Consecutive Chinese-Han patients with ACS who received
maintenance dose of ticagrelor (90 mg, bid) and aspirin (100 mg, qd)
were recruited from General Hospital of Chinese People’s Liberation
Army. After 5 days ticagrelor maintenance treatment, 5umol/L ADP
induced residue platelet aggregation (RPA) by light transmittance
aggregometry (LTA), and platelet inhibition (PIADP) measured by
thrombelastography (TEG) were measured.
RESULTS Overall, 532 ACS patients (Male: 72.56%, Age: 6011 years)
under ticagrelor maintenance treatment were recruited. Antiplatelet
responsiveness measured by LTA was available in 146 patients, and
by TEG in 176 patients. After 5 days’ ticagrelor maintenance dose
therapy, the value of RPA measured by LTA was (13.879.41)% on
average (range from 1.80% to 51%). With the pre-speciﬁc cutoffs for
HTPR (5umol/L ADP induced RPA >40%), 4 patients (2.74%) were
identiﬁed as HTPR. The value of PRA < 10% could be seen in ﬁfty-six
patients (38.36%). The value of PIADP measured by TEG was
(85.9217.79)% on average (ranged from 4.80% to 100%). The distri-
bution curve of both RPA and PIADP values moved to the direction of
strong antiplatelet responsiveness with the possibility of increased
risk for bleeding.
CONCLUSIONS The variability of ticagrelor antiplatelet responsive-
ness could be detected in Chinese ACS patients. Association of the
ticagrelor antiplatelet responsiveness variability to clinical efﬁcacy
and safety outcomes should be evaluated in the future.
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OBJECTIVES High on-treatment platelet reactivity (HTPR) after clo-
pidogrel therapy is accompanied by an increased risk of adverse
outcomes. Direct comparison between ticagrelor and high-dose clo-
pidogrel has not yet been reported in patients with acute myocardial
infarction (AMI) or coronary artery in-stent restenosis (ISR).
METHODS In a prospective, single-center, single-blind, randomized
trial, consecutive patients with AMI or coronary artery ISR treated
with standard-dose clopidogrel (75 mg/day) were screened with the
VerifyNow assay, deﬁning HTPR as P2Y12 reaction units (PRUs) >208.
Of the 102 screened patients, 48 (47.06%) patients with HTPR were
randomly assigned to either ticagrelor (180 mg/90 mg twice daily) or
high-dose clopidogrel (150 mg/day) for 24 hours.
RESULTS Baseline characteristics and mean PRUs were similar in both
groups. After 24 hours, ticagrelor was associated with a signiﬁcantly
lower platelet reactivity than high-dose clopidogrel (44.38  40.26 vs.
212.58  52.34 PRU, P<0.05). No patient receiving ticagrelor exhibited
HTPR, whereas 15 (62.50%) patients after treatment with high-dose
clopidogrel remained HTPR (P<0.05). During the follow-up (mean,
138.42 53.59 days), no patient exhibited a major bleeding event in
either treatment group.
CONCLUSIONS The prevalence of HTPR is high in patients with AMI
or coronary artery ISR after standard clopidogrel treatment. Ticagrelor
is signiﬁcantly more effective compared with high-dose clopidogrel in
overcoming HTPR.
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